Zivo Bioscience Q2 2024: No Revenue, Net Loss

TL;DR

ZIVO: Q2 no revenue, still losing money. Private transactions in July/Aug.

AI Summary

Zivo Bioscience, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported no revenue for the quarter and a net loss. Subsequent events include private transactions occurring between July 1 and August 9, 2024, related to the company's incentive plans.

Why It Matters

This filing indicates Zivo Bioscience's continued lack of revenue generation and ongoing net losses, which could impact its financial stability and future operations.

Risk Assessment

Risk Level: high — The company has no reported revenue and continues to incur losses, indicating significant financial risk.

Key Numbers

• $0.001 — Revenue (Reported for the quarter ending June 30, 2024, indicating no significant sales.)
• $3,319,032 — Net Loss (Incurred during the period, highlighting ongoing operational costs exceeding income.)
• $2,382,356 — Net Loss (Incurred during the prior comparable period, showing a potential increase in losses.)

Key Players & Entities

• Zivo Bioscience, Inc. (company) — Filer of the 10-Q
• 20240630 (date) — End of the reporting period
• 20240814 (date) — Filing date of the 10-Q
• 2024-07-01 (date) — Start date for subsequent private transactions
• 2024-08-09 (date) — End date for subsequent private transactions

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share ZIVO OTCQB Warrants to p
• $172,670 — ed June 30, 2024, the Company exchanged $172,670 in accounts payable to related parties
• $400,000 — n stock for an accrued bonus payable of $400,000 to the Company's CEO (see NOTE 4 - STOC
• $1.20 — ing stock price on December 29, 2023 of $1.20 per share . The value of the shares g

Filing Documents

• zivo_10q.htm (10-Q) — 749KB
• zivo_ex311.htm (EX-31.1) — 14KB
• zivo_ex312.htm (EX-31.2) — 14KB
• zivo_ex321.htm (EX-32.1) — 5KB
• zivo_ex322.htm (EX-32.2) — 5KB
• 0001654954-24-010644.txt ( ) — 3360KB
• zivo-20240630.xsd (EX-101.SCH) — 34KB
• zivo-20240630_lab.xml (EX-101.LAB) — 193KB
• zivo-20240630_cal.xml (EX-101.CAL) — 34KB
• zivo-20240630_pre.xml (EX-101.PRE) — 157KB
• zivo-20240630_def.xml (EX-101.DEF) — 92KB
• zivo_10q_htm.xml (XML) — 493KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION.

Condensed Financial Statements (Unaudited)

Item 1. Condensed Financial Statements (Unaudited) 3

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. 16

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk. 24

Controls and Procedures

Item 4. Controls and Procedures. 24

- OTHER INFORMATION

PART II - OTHER INFORMATION.

Legal Proceedings

Item 1. Legal Proceedings. 27

Risk Factors

Item 1A. Risk Factors. 27

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. 27

Defaults upon Senior Securities

Item 3. Defaults upon Senior Securities. 28

Mine Safety Disclosures

Item 4. Mine Safety Disclosures. 28

Other Information

Item 5. Other Information. 28

Exhibits

Item 6. Exhibits 29 Page 2 of 30 Table of Contents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements ZIVO BIOSCIENCE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) June 30, December 31, 2024 2023 ASSETS CURRENT ASSETS: Cash $ 2,466 $ 274,380 Accounts receivable - 3,735 Prepaid expenses 492,661 147,262 Total current assets 495,127 425,377 OTHER ASSETS: Operating lease - right of use asset 48,403 98,280 Security deposit 32,058 32,058 Total other assets 80,461 130,338 TOTAL ASSETS $ 575,588 $ 555,715 CURRENT LIABILITIES: Accounts payable $ 1,093,469 $ 993,090 Accounts payable – related party 79,405 172,670 Customer deposits 15,000 - Current portion of long-term operating lease 50,920 106,342 Convertible debentures payable 240,000 240,000 Loan Payable 287,533 - Accrued interest 101,876 100,686 Accrued liabilities – employee bonus 1,002,999 1,148,770 Total current liabilities 2,871,202 2,761,558 LONG TERM LIABILITIES: - - TOTAL LIABILITIES 2,871,202 2,761,558 COMMITMENTS AND CONTINGENCIES STOCKHOLDERS' EQUITY (DEFICIT): Common stock, $ 0.001 par value, 25,000,000 shares authorized as of June 30, 2024 and December 31, 2023; 3,319,032 and 2,382,356 issued and outstanding at June 30, 2024, and December 31, 2023, respectively 3,319 2,382 Additional paid-in capital 130,797,635 121,373,488 Accumulated deficit ( 133,096,568 ) ( 123,581,714 ) Total stockholders' equity (deficit) ( 2,295,614 ) ( 2,205,844 ) TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) $ 575,588 $ 555,715 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Page 3 of 30 Table of Contents ZIVO BIOSCIENCE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) For the Three Months ended June 30, 2024 For the Three Months ended June 30, 2023 For the Six Months ended June 30, 2024 For the Six Months e

View Full Filing

View this 10-Q filing on SEC EDGAR